Good to see they have seen the light and stopped the trial.
Unfortunately, they have not understood that the same rational used to stop this indication/trial puts the other "indications" at the same disadvantage. I am concerned this is still partial sunk cost thinking.
They should find a completely new project and move on with the cash (there are plenty to choose from). A cashed up, listed biotech would have its pick of several wonderful current opportunities and would be in the driver's seat given the difficulty companies are having raising cash..
IXC Price at posting:
17.0¢ Sentiment: None Disclosure: Not Held
